IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Precision medicine becomes reality-tumor type-agnostic therapy
Yan, Li1,2; Zhang, Wei3
通讯作者Yan, Li(1,2)
关键词Precision medicine Anti-programmed cell death-1 Microsatellite instability-high Deficient DNA mismatch repair
刊名CANCER COMMUNICATIONS
2018-03-31
DOI10.1186/s40880-018-0274-3
38
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]MISMATCH-REPAIR DEFICIENCY ; MICROSATELLITE INSTABILITY ; PD-1 BLOCKADE ; ANTI-PD-1 ANTIBODY ; LYNCH SYNDROME ; SOLID TUMORS ; CANCER ; SAFETY ; FUSION
英文摘要

Precision medicine just witnessed two breakthroughs in oncology in 2017. Pembrolizumab (Keytruda), Merck′s antiprogrammed cell death-1 (PD-1) monoclonal antibody (mAb), received accelerated approval in May 2017 by the US Food and Drug Administration for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having microsatellite instability-high (MSI-H) or deficient DNA mismatch repair (dMMR). Shortly after, nivolumab (Opdivo), Bristol-Myers Squibb′s anti-PD-1 mAb, gained an accelerated approval in August 2017 for adult and pediatric patients with MSI-H or dMMR metastatic colorectal cancer that has progressed after standard chemotherapy. These regulatory approvals marked an important milestone that a cancer treatment may be approved based on a common biomarker rather than the anatomic location in the body where the tumor originated, and therefore established a precedent for tumor type-agnostic therapy. In the 2017 American Society for Clinical Oncology annual meeting, larotrectinib (LOXO-101), Loxooncology′s oral, potent, and selective inhibitor of tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK)-fusion proteins in adult and pediatric patients. Both the anti-PD-1 mAbs and the TRK-targeting therapies share some basic features: (a) biomarker-based, well-defined rare patient population; (b) exceptionally high clinical efficacy, e.g., near 40% overall response rate (ORR) for pembrolizumab across 15 tumor types with MSI-H/dMMR and 75% ORR for larotrectinib across more than 12 tumor types with NTRK-fusion proteins; (c) durable responses lasting at least 6 months with complete responses observed; and (d) parallel development in adult and pediatric populations. With increasing accessibility to genetic analysis tools such as next-generation sequencing, tumor type-agnostic therapy has become a reality, both during clinical development and in clinical practice. Adjustments in our approaches to developing new anti-cancer drugs and to adopting these new cancer treatments in clinical practice need to occur in order to prepare ourselves for the new era of precision medicine.

语种英语
WOS记录号WOS:000434479100002
通讯作者邮箱ynyinternational@yahoo.com
第一作者单位US Chinese Anticanc Assoc, Martinez, CA 94553 USA ; Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China
通讯作者单位US Chinese Anticanc Assoc, Martinez, CA 94553 USA ; Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China
ISSN2523-3548
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/142262
专题北京大学临床肿瘤学院
作者单位1.US Chinese Anticanc Assoc, Martinez, CA 94553 USA;
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China;
3.Wake Forest Baptist Comprehens Canc Ctr, Canc Genom & Precis Oncol, Winston Salem, NC 27157 USA
推荐引用方式
GB/T 7714
Yan, Li,Zhang, Wei. Precision medicine becomes reality-tumor type-agnostic therapy[J]. CANCER COMMUNICATIONS,2018,38.
APA Yan, Li,&Zhang, Wei.(2018).Precision medicine becomes reality-tumor type-agnostic therapy.CANCER COMMUNICATIONS,38.
MLA Yan, Li,et al."Precision medicine becomes reality-tumor type-agnostic therapy".CANCER COMMUNICATIONS 38(2018).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yan, Li]的文章
[Zhang, Wei]的文章
百度学术
百度学术中相似的文章
[Yan, Li]的文章
[Zhang, Wei]的文章
必应学术
必应学术中相似的文章
[Yan, Li]的文章
[Zhang, Wei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。